C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

Slides:

Advertisements

Similar presentations

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Advertisements

The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa.

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment Winnie Ridderberg, Karen E.M.

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves.

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis Tavs Qvist,

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Cytokine gene polymorphisms and severity of CF lung disease

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis C.S. Dalbøge, X.C. Nielsen, K. Dalhoff,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

Soluble inflammation markers in nasal lavage from CF patients and healthy controls Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Beta-lactam allergy in adults with cystic fibrosis

Airway inflammation in mild cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Treatment intensity and characteristics of MRSA infection in CF

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Segregation—the perspectives of young patients and their parents

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients C.R. Hansen, T. Pressler, K.G. Nielsen, P.Ø. Jensen, T. Bjarnsholt, N. Høiby Journal of Cystic Fibrosis Volume 9, Issue 1, Pages 51-58 (January 2010) DOI: 10.1016/j.jcf.2009.10.005 Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 A. xylosoxidans biofilm in CF sputum. Biofilm found in sputum from a CF patient chronically infected with A. xylosoxidans for 7.5years. Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Change in FEV1, % predicted/year, up to 12years of chronic infection. Figure shows individual values, mean and 95% confidence interval: A. xylosoxidans: −1.9 (−0.2 to −3.6), Bcc: −3.6 (−4.9 to −2.2) and P. aeruginosa: −1.1 (−2.2 to +0.05) (p<0.005). Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Level of TNF-α (pg/ml) in serum. Figure shows individual values, mean and 95% confidence interval: Healthy controls: 8.2 (6.9–9.9), CF without chronic infection: 11.4 (9.9–12.8), A. xylosoxidans: 10.4 (8.7–12), Bcc: 12.7 (9.6–15.8), P. aeruginosa: 10.8 (8.7–12.9) (p<0.003). Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Level of G-CSF (pg/ml) in serum. Figure shows individual values, mean and 95% confidence interval: Healthy controls: 39 (24–54.1), CF without chronic infection: 66.5 (38.6–94.3), A. xylosoxidans: 133 (49.8–216.2), Bcc: 60.4 (41.4–79.4), P. aeruginosa: 111.1 (57–165.3) (p<001). Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 5 Level of IL-6 (pg/ml) in serum. Figure shows individual values, mean and 95% confidence interval: Healthy controls: 9.2 (−4–22.4), CF without chronic infection: 11.7 (1.6–21.8), A. xylosoxidans: 23.7 (8.1–39.2), Bcc: 17.3 (2.1–32.6), P. aeruginosa: 25.6 (14.1–37.1) (p<0.003). Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 6 IFN-γ (pg/ml) in serum. Figure shows individual values, mean and 95% confidence interval: Healthy controls: 83.6 (14.5–152.8), CF without chronic infections: 34.7 (6–63.4), A. xylosoxidans: 34.4 (11.1–57.7), Bcc: 102.3 (−9.3–213.9), P. aeruginosa: 86.8 (7.2–166.4) (p<0.04). Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions

Fig. 7 Level of TNF-α (pg/ml) in sputum. Figure shows individual values, mean and 95% confidence interval: A. xylosoxidans: 248.3 (158.1–338.5), Bcc: 129.4 (−8.2–267), P. aeruginosa: 145.8 (14.4–277.2) (p<0.03). Journal of Cystic Fibrosis 2010 9, 51-58DOI: (10.1016/j.jcf.2009.10.005) Copyright © 2009 European Cystic Fibrosis Society Terms and Conditions